LXEOLexeo Therapeutics, Inc.
Earnings
When Lexeo Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.
19 quarters. Mar 31, 2022 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Mar 29, before the open
Mon, Mar 29, 2027in 132 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 5 – Apr 6
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Net income
- -$20.96M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- —
- —
- Net income
- -$38.30M
- N/M
- EPS
- -$0.43
- N/M
- Revenue
- —
- —
- Net income
- -$25.87M
- N/M
- EPS
- -$0.30
- N/M
- Revenue
- —
- —
- Net income
- -$20.20M
- N/M
- EPS
- -$0.25
- N/M
- Revenue
- —
- —
- Net income
- -$20.96M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 16, 2026 · pre-market | Nov 16, 2026 | 47 d | 10-Q | — | — | -$0.43 | — | |
| Q2 2026 | Jun 30, 2026 | Aug 12, 2026 · pre-market | Aug 12, 2026 | 43 d | 10-Q | — | — | -$0.30 | +1.7% | |
| Q1 2026 | Mar 31, 2026 | May 11, 2026 · pre-market | May 11, 2026 | 41 d | 10-Q | — | — | -$0.25 | +5.2% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Mar 30, 2026 · after-hours | Mar 30, 2026 | 89 d | 10-K | — | — | — | +9.3% | |
| Q3 2025 | Sep 30, 2025 | Nov 5, 2025 · pre-market | Nov 5, 2025 | 36 d | 10-Q | — | — | -$0.33 | 2.0% | |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 · pre-market | Aug 14, 2025 | 45 d | 10-Q | — | — | -$0.60 | 0.2% | |
| Q1 2025 | Mar 31, 2025 | May 12, 2025 · pre-market | May 12, 2025 | 42 d | 10-Q | — | — | -$0.99 | 1.9% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Mar 24, 2025 · pre-market | Mar 24, 2025 | 83 d | 10-K | — | — | — | +51.2% | |
| Q3 2024 | Sep 30, 2024 | Nov 13, 2024 · pre-market | Nov 13, 2024 | 44 d | 10-Q | — | — | -$0.89 | +0.3% | |
| Q2 2024 | Jun 30, 2024 | Aug 12, 2024 · pre-market | Aug 12, 2024 | 43 d | 10-Q | — | — | -$0.64 | +4.2% | |
| Q1 2024 | Mar 31, 2024 | May 9, 2024 · pre-market | May 9, 2024 | 39 d | 10-Q | — | — | -$0.77 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Mar 11, 2024 · after-hours | Mar 11, 2024 | 71 d | 10-K | — | — | — | +8.3% | |
| Q3 2023 | Sep 30, 2023 | Dec 11, 2023 · pre-market | Dec 11, 2023 | 72 d | 10-Q | — | — | -$12.36 | — | |
| Q2 2023 | Jun 30, 2023 | — | — | — | — | — | — | -$8.30 | — | |
| Q1 2023 | Mar 31, 2023 | — | — | — | — | — | — | -$11.58 | — | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | — | — | — | — | — | — | — | — | |
| Q3 2022 | Sep 30, 2022 | — | — | — | — | $531.00K | — | -$10.38 | — | |
| Q2 2022 | Jun 30, 2022 | — | — | — | — | — | — | — | — | |
| Q1 2022 | Mar 31, 2022 | — | — | — | — | — | — | — | — | |
Earlier years, FY 2022 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Lexeo Therapeutics, Inc. · CIK 1907108 · Engraved from SEC EDGAR